Compare WNC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | CABA |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 495.7M |
| IPO Year | 2009 | 2019 |
| Metric | WNC | CABA |
|---|---|---|
| Price | $12.52 | $2.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $14.50 |
| AVG Volume (30 Days) | 643.1K | ★ 4.7M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 179.22 | 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.63 | $1.82 |
| 52 Week High | $14.47 | $4.23 |
| Indicator | WNC | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 40.12 |
| Support Level | $11.65 | $2.58 |
| Resistance Level | $13.02 | $3.41 |
| Average True Range (ATR) | 0.65 | 0.24 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 33.95 | 8.02 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.